Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - vladimir muzykantov

4 Results Sort By:
Targeted drug delivery using red-blood cells for transport
Platform technology for targeted drug delivery using red blood cells for transport. Problem: Drug delivery can often result in up to 99% of the drug being delivered to off-target organs. This can lead to side-effects and toxicities. Current methods that bind drugs to red-blood cells for transport can require modifying the structure of the red...
Published: 6/23/2020   |   Inventor(s): Laura Ferguson, Elizabeth Hood, Carlos Villa, Jacob Brenner, Vladimir Muzykantov
Keywords(s): Acute Lung Injury, Cardiovascular, COVID-19, Drug Delivery, Nanotechnology, Respiratory
Category(s): Therapeutics & Vaccines
Targeted, efficient, and safe intracellular drug delivery via nanocarriers
Cytosolic drug delivery using DNA-based nanocarriers coated with cell-targeted antibodies. Problem: The ability to deliver drugs intracellularly is critical for the treatment of diseases caused by aberrant processes within the cell. However, current drug delivery methods are ineffective at reaching the cell interior beyond the membranes of the endocytic...
Published: 5/20/2020   |   Inventor(s): Vladimir Muzykantov, Silvia Muro-Galindo
Keywords(s): Drug Delivery
Category(s): Research Tools & Reagents, Therapeutics & Vaccines
Targeting drugs to circulating red blood cells
Problem: Annual incidence of venous thrombosis in the U.S. is 1 to 2 per 1000 adults. Roughly 33% of those presenting with a thrombotic event will have recurrence within 10 years. Thrombosis can cause tissue ischemia and damage leading to severe complications and possible mortality. Conditions associated with uncontrolled acute inflammation such...
Published: 3/9/2020   |   Inventor(s): Vladimir Muzykantov
Keywords(s):  
Category(s): Therapeutics & Vaccines
Improving drug delivery using red blood cell hitchhiking
Problem: A major challenge in drug delivery is ensuring that the drug reaches the target organ at a concentration sufficient to treat the disease. This is particularly problematic for acute illnesses of the vasculature, such as acute respiratory distress syndrome (ARDS), ischemic stroke, and myocardial infarction. In these diseases, patients are often...
Published: 2/13/2020   |   Inventor(s): Jacob Brenner, Vladimir Muzykantov
Keywords(s): COVID-19
Category(s): Therapeutics & Vaccines